Leaders of Zhangjiang Biotech&Pharmaceutical Base visited Qure Bio for investigation and research

March. 08, 2022

On March 4th, Lou Qi, general manager of Zhangjiang Biotech&Pharmaceutical Base, and Cao Li, assistant to the general manager, and other leaders visited Qure Bio for investigation and research. Dr. Du Yejie, deputy general manager of Qure Bio, received and accompanied the visit.

Dr. Du Yejie introduced the company's basic situation to the leaders of Zhangjiang Biotech&Pharmaceutical Base, and reported the company's latest progress and achievements in the field of innovative drugs. Dr. Du Yejie said that Qure Bio is an international company focusing on the research and development of innovative macromolecular biological drugs. The company's goal is to continuously develop new therapeutic drugs for intractable cancers, autoimmune diseases and metabolic diseases to benefit patients in China and the world. At present, Qure Bio has established a wealth of macromolecular biopharmaceutical R & D pipelines, of which the Q-1802 project (claudin18.2 / PD-L1 bispecific antibody) has entered phase I clinical trial. In the follow-up, preclinical studies of multiple projects will be completed and applied for clinical trials. At the same time, Qure Bio has a number of core technology platforms for antibody development, including: hybridoma antibody humanization platform, phage display platform, nano/single domain antibody platform, antibody engineering technology platform, high-yield cell line development platform, process optimization platform, etc. .

The leaders of Zhangjiang Biotech&Pharmaceutical Base highly praised Qure Bio's progress in innovative drug research and development, and affirmed the company's exploratory spirit of insisting on independent research and development, being brave in innovation, and keeping pace with the world, and they full of expectations for the realization of Qure Bio's future development plan. At the same time, they expressed that they will give full support in terms of talent policy and government financial support.

Qure Bio expressed its sincere gratitude to the leaders of Zhangjiang Biotech&Pharmaceutical Base for their concern, and will continue to maintain the spirit of innovation and exploration, develop the most promising biological target drugs, create and master new value-added platforms, and build a rich and robust biological drug pipeline. Based on this, Qure Bio will comprehensively promote the molecular structure innovation, process development and clinical research of biological drugs, and establish a new development pattern.